1. Claridy MD, Czepiel KS, Bajaj SS, Stanford FC. Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016. Mayo Clin Proc. 2021 Dec;96(12):2991-3000. doi: 10.1016/j.mayocp.2021.07.021. Epub 2021 Oct 30. PMID: 34728060; PMCID: PMC8649050.
2. Elangovan A, Shah R, Smith ZL. Pharmacotherapy for Obesity-Trends Using a Population Level National Database. Obes Surg. 2021 Mar;31(3):1105-1112. doi: 10.1007/s11695-020-04987-2. Epub 2020 Sep 28. PMID: 32986169.
3. Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019 Aug;7(16):393. doi: 10.21037/atm.2019.07.27. PMID: 31555707; PMCID: PMC6736799.
4. Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018 Mar;130(2):173-182. doi: 10.1080/00325481.2018.1435129. Epub 2018 Feb 8. PMID: 29388462; PMCID: PMC6261426.
5. Wang C, Shi W, Xu J, Huang C, Zhu J. Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial. Ann Gen Psychiatry. 2020 Dec 10;19(1):68. doi: 10.1186/s12991-020-00319-x. PMID: 33302986; PMCID: PMC7727176.
6. Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W, Peterson C, Siegel R. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020 Apr;22(4):480-491. doi: 10.1111/dom.13910. Epub 2019 Dec 18. PMID: 31696603.
7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Lorcaserin. [Updated 2020 Jun 5]. https://www.ncbi.nlm.nih.gov/books/NBK548834/
8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Naltrexone-Bupropion. [Updated 2020 Jun 5]. https://www.ncbi.nlm.nih.gov/books/NBK559444/
9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Liraglutide. [Updated 2019 Apr 10]. https://www.ncbi.nlm.nih.gov/books/NBK548472/
10. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022 Mar;21(3):201-223. doi: 10.1038/s41573-021-00337-8. Epub 2021 Nov 23. PMID: 34815532; PMCID: PMC8609996.
11. Rosa-Gonçalves P, Majerowicz D. Pharmacotherapy of Obesity: Limits and Perspectives. Am J Cardiovasc Drugs. 2019 Aug;19(4):349-364. doi: 10.1007/s40256-019-00328-6. PMID: 30793263.
12. Shahabadi N, Zendehcheshm S, Mahdavi M, Khademi F. Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach. Inform Med Unlocked. 2021;26:100745. doi: 10.1016/j.imu.2021.100745. Epub 2021 Sep 22. PMID: 34568544; PMCID: PMC8455240.
13. Liang Q, Zhuang Y, Ma J, Wang J, Feng R, He R, Luo Z, Wang H, Zhan R. A Rapid Screening Method for Sibutramine Hydrochloride in Natural Herbal Medicines and Dietary Supplements. Int J Anal Chem. 2021 Aug 25;2021:8889423. doi: 10.1155/2021/8889423. PMID: 34484342; PMCID: PMC8413021.
14. Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. PMID: 33410104; PMCID: PMC7787121.
15. Sombra LRS, Anastasopoulou C. Pharmacologic Therapy For Obesity. [Updated 2022 Jul 24]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK562269/
16. Ohishi T, Fukutomi R, Shoji Y, Goto S, Isemura M. The Beneficial Effects of Principal Polyphenols from Green Tea, Coffee, Wine, and Curry on Obesity. Molecules. 2021 Jan 16;26(2):453. doi: 10.3390/molecules26020453. PMID: 33467101; PMCID: PMC7830344.
17. Lin Y, Shi D, Su B, Wei J, Găman MA, Sedanur Macit M, Borges do Nascimento IJ, Guimaraes NS. The effect of green tea supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytother Res. 2020 Oct;34(10):2459-2470. doi: 10.1002/ptr.6697. Epub 2020 May 5. PMID: 32372444.
18. Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008.
19. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183.
20. ASHP. Semaglutide. 2024. https://www.drugs.com/monograph/semaglutide.html